Integrative exploration of 2-phenylquinolin-4(1H)-one tethered 1,2,3-triazole derivatives: A comprehensive in vitro and in silico investigation towards novel anti-tubercular agents
{"title":"Integrative exploration of 2-phenylquinolin-4(1H)-one tethered 1,2,3-triazole derivatives: A comprehensive in vitro and in silico investigation towards novel anti-tubercular agents","authors":"Raut Mehavi , Walhekar Vinayak , Patil Ashwini , Pavan Kumar Jaini , Mohana Vamsi Nuli , Bhikshapathi DVRN , Ravindra Kulkarni","doi":"10.1016/j.tube.2025.102628","DOIUrl":null,"url":null,"abstract":"<div><div>Novel 2-phenylquinolin-4(1<em>H</em>)-one threaded 1,2,3- triazoles were designed, synthesized and evaluated for <em>in vitro</em> activity against <em>Mycobacterium tuberculosis</em> which could be putatively through inhibition of carbonic anhydrase <em>β</em>. Molecules were synthesized in simple Schottan Baumann reaction for amide synthesis. Purified compounds were screened for antitubercular and antibacterial activities. Among them, 1-((1-(2-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-phenylquinolin-4(1<em>H</em>)-one <strong>9j</strong> with 2-methoxy at the ortho position of phenyl ring indicated significant antitubercular activity with MIC value of <strong>6.25, 3.12</strong> and <strong>3.12 μg/ml</strong> antimicrobial activity against <em>Mycobacterium tuberculosis,</em> gram positive and gram negative strain. The molecular docking and dynamics studies demonstrated that the compound <strong>9j</strong> occupied the Zn-binding site of the enzyme with docking energy of <strong>-6.2 kcal mol<sup>−1</sup></strong>. <em>In silico</em> ADME studies indicated that the synthesized compounds have good drug likeliness. The findings explore and present a potential series of antimycobacterial agents in the hope of developing new and advanced therapeutics for tuberculosis.</div></div>","PeriodicalId":23383,"journal":{"name":"Tuberculosis","volume":"152 ","pages":"Article 102628"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S147297922500023X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Novel 2-phenylquinolin-4(1H)-one threaded 1,2,3- triazoles were designed, synthesized and evaluated for in vitro activity against Mycobacterium tuberculosis which could be putatively through inhibition of carbonic anhydrase β. Molecules were synthesized in simple Schottan Baumann reaction for amide synthesis. Purified compounds were screened for antitubercular and antibacterial activities. Among them, 1-((1-(2-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-phenylquinolin-4(1H)-one 9j with 2-methoxy at the ortho position of phenyl ring indicated significant antitubercular activity with MIC value of 6.25, 3.12 and 3.12 μg/ml antimicrobial activity against Mycobacterium tuberculosis, gram positive and gram negative strain. The molecular docking and dynamics studies demonstrated that the compound 9j occupied the Zn-binding site of the enzyme with docking energy of -6.2 kcal mol−1. In silico ADME studies indicated that the synthesized compounds have good drug likeliness. The findings explore and present a potential series of antimycobacterial agents in the hope of developing new and advanced therapeutics for tuberculosis.
期刊介绍:
Tuberculosis is a speciality journal focusing on basic experimental research on tuberculosis, notably on bacteriological, immunological and pathogenesis aspects of the disease. The journal publishes original research and reviews on the host response and immunology of tuberculosis and the molecular biology, genetics and physiology of the organism, however discourages submissions with a meta-analytical focus (for example, articles based on searches of published articles in public electronic databases, especially where there is lack of evidence of the personal involvement of authors in the generation of such material). We do not publish Clinical Case-Studies.
Areas on which submissions are welcomed include:
-Clinical TrialsDiagnostics-
Antimicrobial resistance-
Immunology-
Leprosy-
Microbiology, including microbial physiology-
Molecular epidemiology-
Non-tuberculous Mycobacteria-
Pathogenesis-
Pathology-
Vaccine development.
This Journal does not accept case-reports.
The resurgence of interest in tuberculosis has accelerated the pace of relevant research and Tuberculosis has grown with it, as the only journal dedicated to experimental biomedical research in tuberculosis.